ong-term immunity after primary vaccination against tick-borne encephalitis in the elderly

Phase 1

• Conditions: long-term B-cell immunity against tick-borne encephalitis (TBE) in healthy volunteers who have received 3-dose primary vaccination at an age between 18 and 31 years or older than 60 years.; Therapeutic area: Body processes [G] - Immune system processes [G12]

• Registration Number: EUCTR2012-004231-24-AT
• Lead Sponsor: Department für Virologie, Medizinische Universität Wien

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-02-15
• Last Update Posted: 5 September 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Volunteers that have received 3-dose primary TBE vaccination in the primary study 3 years ago.
TBE-vaccination criteria fulfilled.
Participants of the primary study who have received 3-dose primary TBE vaccination but did not participate in the follow-up analysis will also be included.
All participants have to understand and sign informed consent form (based on the judgement of the study physician)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 21

Exclusion Criteria

Contraindication to TBE vaccination (according to SmPC 2007)
Immunodeficiency, history of autoimmune disease or current intake of immunomodulating drugs (corticosteroids)
Pregnancy

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified